EGM
PSTV

Engineers Gate Manager’s Plus Therapeutics PSTV Stock Holding History

Engineers Gate Manager’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31
Closed -$28K – 1861
2019
Q4 		$28K Buy
+31
New +$28.4K ﹤0.01% 1578

Other funds holding PSTV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
FP
Financial Perspectives Minneapolis, Minnesota $411M AUM 26.27% 1-Year Est. Return

Engineers Gate Manager's PSTV Position: Q1 2020 in Review

Engineers Gate Manager sold out of Plus Therapeutics (PSTV) in Q1 2020, closing a stake of 31 shares — an estimated $28K sold.

Engineers Gate Manager first reported a position in PSTV in Q4 2019 and held it in 1 quarter. The position peaked at $28K in Q4 2019. 5 funds tracked by Wall St. Rank hold PSTV as of Q1 2020.

  • Engineers Gate Manager reported no remaining Plus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Engineers Gate Manager sold 31 Plus Therapeutics shares in Q1 2020, an estimated $28K.
  • Engineers Gate Manager first reported a position in Plus Therapeutics in Q4 2019 and held it in 1 quarter.
  • Engineers Gate Manager's Plus Therapeutics position peaked at $28K in Q4 2019.
  • 5 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2020.

Based on Engineers Gate Manager's 13F filing for Q1 2020, filed 15 May 2020.